Ready for Transfer

CDC-AGO, a Targeted Mosquito Trap

Dept. of Health and Human Services

Laboratory: Centers for Disease Control and Prevention

Technology: Autocidal Gravid Ovitrap Mosquito Trap for Control and Surveillance of Mosquitoes

Opportunity: Available for licensing

Details: Mosquitoes are responsible for the transmission of a number of important zoonotic diseases, including dengue fever, malaria, zika, Rift Valley fever, and West Nile virus. The CDC-AGO (Autocidal Gravid Ovitrap) mosquito trap is a device that targets older female mosquitoes looking for a suitable place to lay eggs. This device is 45 centimeters tall with a 10-liter capacity to hold an attractant, such as water and decaying vegetation. The mosquitoes are captured by a nontoxic adhesive, and eggs are collected on a hydrogel. The use of the hydrogel instead of a liquid prevents the larvae from hatched mosquito eggs from completing development.

Benefits: Over time, insecticide compounds degrade and mosquito populations can become insecticide-resistant, so many chemical ovitraps currently on the market are short-lived. Unlike other mosquito control methods, the CDC-AGO addresses this need with its use of nontoxic adhesive and hydrogel polymer instead of insecticide.

Potential Applications:

  • Device for mosquito control
  • May be useful in regions of the world affected by vector-borne zoonotic diseases


Contact: For more information about this award-winning technology, contact  or Lisa Marianni, RN, MBA at

View the original listing for this technology from the National Institutes of Health’s Office of Technology Transfer, which administers the CDC’s technology transfer program.